REG-Arix Bioscience PLC Correction: Result of Annual General Meeting

Arix BioscienceAnnouncement

24/05/2023 07:15

============

Arix Bioscience PLC (ARIX)
Correction: Result of Annual General Meeting

24-May-2023 / 07:00 GMT/BST

══════════════════════════════════════════════════════════════════════════════════

 

                                         

The following amendment has been made to the ‘Arix Bioscience plc Result of Annual
General Meeting' announcement released  on 23/05/2023 at 16:30  under EQS News  ID
1639935.

 

Website links  to the  full details  of the  Arix investor  relations website  and
National Storage Mechanism have been reinserted, owing to a text conversion  error
on the EQS platform.

 

All other information remains unchanged. The fully amended text is shown below:

                                         

                               Arix Bioscience plc

                                         

                         Result of Annual General Meeting

 

LONDON, 24 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX),  a
transatlantic  venture  capital  company  focused  on  investing  in  breakthrough
biotechnology companies,  announces  that  at  its  Annual  General  Meeting  (the
"Meeting") duly convened and held today, all resolutions as set out on the  notice
of meeting were duly passed by way of  a poll. Resolutions 1 to 11 were passed  as
ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

 

Full details of the poll results are set  out below and will also be available  on
the                             Company's website                              at:
 1 https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=

 

                                        VOTES                       % of   VOTES
No   RESOLUTION    VOTES FOR     %     AGAINST    %    TOTAL VOTES  ISC   WITHHELD
                                                                   VOTED
   To receive the
     Directors'                                                               
   Report and the
1  accounts of the 68,931,411 100.00%   3,441   0.00%  68,934,852  53.28%  8,440
   Company for the
    year ended 31                                                             
    December 2022
   To approve the                                                             
     Directors'
2   Remuneration   61,073,950 89.25%  7,358,207 10.75% 68,432,157  52.89% 511,135
       Report
                                                                              
     To re-elect                                                              
      Peregrine
3  Moncreiffe as a 68,099,019 98.79%   834,821  1.21%  68,933,840  53.28%  9,452
      Director
                                                                              
     To re-elect                                                              
       Maureen
4  O'Connell as a  68,894,053 99.94%   42,077   0.06%  68,936,130  53.28%  7,162
      Director
                                                                              
                                                                              
     To re-elect
5  Isaac Kohlberg  68,900,656 99.98%   17,184   0.02%  68,917,840  53.26%  25,452
    as a Director
                                                                              
                                                                              
     To re-elect
6  Robert Lyne as  68,902,689 99.95%   31,595   0.05%  68,934,284  53.28%  9,008
     a Director
                                                                              
                                                                              
    To elect Dr.
7  Debra Barker as 68,907,528 99.95%   32,248   0.05%  68,939,776  53.28%  3,516
     a Director
                                                                              
                                                                              
   To elect Andrew
8    Smith as a    68,921,195 99.98%   13,089   0.02%  68,934,284  53.28%  9,008
      Director
                                                                              
                                                                              
   To appoint BDO
9  LLP as auditors 68,929,881 99.99%    7,445   0.01%  68,937,326  53.28%  5,966
   of the Company
                                                                              
    To authorise
    the Audit and                                                             
   Risk Committee
10 of the Company  68,934,245 100.00%   2,013   0.00%  68,936,258  53.28%  7,034
     to fix the
      auditor's                                                               
    remuneration
                                                                              
    To authorise
11  the Directors  65,989,256 95.72%  2,950,520 4.28%  68,939,776  53.28%  3,516
   to allot shares
                                                                              
    Authority to                                                              
      disapply
12 statutory pre‐  62,199,252 90.23%  6,734.680 9.77%  68,933,932  53.28%  9,360
   emption rights
                                                                              
     Additional                                                               
    authority to
13    disapply     62,202,105 90.23%  6,731,827 9.77%  68,933,932  53.28%  9,360
   statutory pre‐
   emption rights                                                             
    To authorise                                                              
   the Company to
14  purchase its   68,921,128 99.98%   17,177   0.02%  68,938,305  53.28%  4,987
     own shares
                                                                              
    Authority to
   call a general
   meeting, other                                                             
   than an annual
15     general     68,145,351 98.85%   792,954  1.15%  68,938,305  53.28%  4,987
   meeting, on not
    less than 14                                                              
     clear days'
       notice

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting
concerning items other than ordinary business will shortly be available for
inspection on the National Storage Mechanism, which can be accessed
here:  2 https://data.fca.org.uk/#/nsm/nationalstoragemechanism   

The full text of the resolutions considered at the AGM are contained in the Notice
of AGM, published on 25 April 2023, which is available on Arix investor
relations website at:
 3 https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=

                                       ENDS 

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir 4 @arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

 5 arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on
investing in breakthrough biotechnology companies around cutting-edge advances in
life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise,
and networks to help accelerate their ideas into important new treatments for
patients. As a listed company, we are able to bring this exciting growth phase of
our industry to a broader range of investors.  6 www.arixbioscience.com

 

 

══════════════════════════════════════════════════════════════════════════════════

Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  RAG
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   245808
   EQS News ID:    1639987


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    7 fncls.ssp?fn=show_t_gif&application_id=1639987&application_name=news&site_id=reuters9

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9b0d6244c2117cc00df1d2ae9873a8d5&application_id=1639987&site_id=reuters9&application_name=news
   2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=1e84eb6c3310c93f7fb161c09372521b&application_id=1639987&site_id=reuters9&application_name=news
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9b0d6244c2117cc00df1d2ae9873a8d5&application_id=1639987&site_id=reuters9&application_name=news
   4. mailto:charlotte@arixbioscience.com
   5. mailto:arix@powerscourt-group.com
   6. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1639987&site_id=reuters9&application_name=news


============